CLINICAL_TRIALS ClinicalTrials.gov record update

Post-Marketing Surveillance of Safety and Effectiveness of Iclusig® Tablets in Korean Patients With CML or Ph+ ALL Under the "Risk Management Plan"

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03709017
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:53.105724+00:00
Published At: 2022-12-07T00:00:00+00:00
Record Updated At: 2022-12-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Chronic Myeloid Leukemia", "Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-12-07"
protocolSection.identificationModule.nctId: "NCT03709017"
protocolSection.identificationModule.officialTitle: "Post-Marketing Surveillance of Safety and Effectiveness of Iclusig\u00ae Tablets in Korean Patients With CML or Ph+ ALL Under the \"Risk Management Plan\""
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.